4582.T Stock - SymBio Pharmaceuticals Limited
Unlock GoAI Insights for 4582.T
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.45B | $5.59B | $10.01B | $8.25B | $2.99B |
| Gross Profit | $1.87B | $4.41B | $7.60B | $5.80B | $866.85M |
| Gross Margin | 76.4% | 78.9% | 75.9% | 70.3% | 29.0% |
| Operating Income | $-3,876,971,000 | $-811,668,000 | $1.96B | $1.02B | $-4,506,220,000 |
| Net Income | $-3,833,480,000 | $-1,962,817,000 | $1.18B | $2.03B | $-4,090,216,000 |
| Net Margin | -156.3% | -35.1% | 11.8% | 24.6% | -136.9% |
| EPS | $-85.00 | $-49.19 | $30.20 | $53.04 | $-124.13 |
SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs in the areas of oncology and hematology in Japan. It is involved in the development of Treakisym SyB L-0501, an anti-cancer agent, which is marketed for the treatment of non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia under the TREAKISYM name; and is in the Phase III clinical trial to treat relapsed/refractory diffuse large B-cell lymphoma. The company also engages in the development of SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid formulation. In addition, it is involved in the development of SyB L-1101, an intravenous formulation, which is in Phase III clinical trial for the treatment of higher-risk myelodysplastic syndromes (HR-MDS); and SyB C-1101, an oral formulation that is in Phase II/III clinical trial in combination with Azacitidine to treat HR-MDS. Further, it engages in the development of SyB V-1901, an antiviral drug for the treatment of infectious diseases. SymBio Pharmaceuticals Limited was incorporated in 2005 and is based in Tokyo, Japan.
Visit WebsiteEarnings History & Surprises
4582.TEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 5, 2026 | — | — | — | — |
Q4 2025 | Oct 30, 2025 | — | $-24.10 | — | — |
Q3 2025 | Jul 31, 2025 | — | $-22.16 | — | — |
Q2 2025 | May 8, 2025 | — | $-27.95 | — | — |
Q1 2025 | Feb 6, 2025 | — | $-21.56 | — | — |
Q4 2024 | Oct 31, 2024 | — | $-28.44 | — | — |
Q3 2024 | Aug 1, 2024 | — | $-16.75 | — | — |
Q2 2024 | May 7, 2024 | — | $-18.03 | — | — |
Q1 2024 | Feb 8, 2024 | — | $-28.90 | — | — |
Q4 2023 | Nov 14, 2023 | — | $-17.83 | — | — |
Q3 2023 | Aug 3, 2023 | — | $-2.12 | — | — |
Q2 2023 | Apr 27, 2023 | — | $0.11 | — | — |
Q1 2023 | Feb 9, 2023 | — | $-9.53 | — | — |
Q4 2022 | Nov 8, 2022 | — | $11.33 | — | — |
Q3 2022 | Aug 4, 2022 | — | $24.36 | — | — |
Q2 2022 | May 11, 2022 | — | $4.25 | — | — |
Q1 2022 | Feb 10, 2022 | — | $42.05 | — | — |
Q4 2021 | Nov 11, 2021 | — | $13.89 | — | — |
Q3 2021 | Aug 4, 2021 | — | $0.11 | — | — |
Q2 2021 | May 13, 2021 | — | $-5.49 | — | — |
Latest News
Frequently Asked Questions about 4582.T
What is 4582.T's current stock price?
What is the analyst price target for 4582.T?
What sector is SymBio Pharmaceuticals Limited in?
What is 4582.T's market cap?
Does 4582.T pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to 4582.T for comparison